INTRODUCTION

Type 1 diabetes (T1D), like its more common Type 2 counterpart, has been rising in prevalence and incidence primarily in Western countries [1, 2] (Fig. 1). Insulin replacement therapy has been the primary treatment of all forms of diabetes for almost 100 years, but inadequate control of its delivery has allowed a number of complications to markedly diminish the quality of life of affected individuals, and contributed to an increasingly intolerable financial burden. The realization that a subset of patients presents with an autoimmune form of insulin-dependent diabetes was made in the 1970s [3]. The initial model suggesting the potential pathogenesis of this disorder as a chronic autoimmune disease directed against β cells was proposed by George Eisenbarth in the mid-1980s [4]. This understanding led to subsequent attempts to develop more specific treatments for this autoimmune form of diabetes, initially with immunosuppressive therapies that had proven effective in other chronic autoimmune diseases, including cyclosporine A (CsA) or anti-thymocyte globulin and prednisone [5–7]. Despite initial suggestion of efficacy of CsA, no subsequent study has been able to confirm these initial results. In addition, the lack of lasting effects once CsA was withdrawn and the serious renal toxicity of the drug severely limited enthusiasm for this approach.

Subsequent natural history studies have made the approach to treatment more complex as these studies have demonstrated that underlying autoimmune responses are present for varying periods of time, usually years, in genetically predisposed individuals before the
Calculating autoantibodies against compatibility class II haplotypes (HLA-DR3/4, HLA-DQ8) confer of, and time remaining, before the onset of hyperglycemia can generally help predict the risk quantity) in at-risk individuals, as well as abnormalities in the appearance of overt hyperglycemia. Particular major histocompatibility class II haplotypes (HLA-DR3/4, HLA-DQ8) confer the greatest risk as genetic factors [8]. In addition to serving as a diagnosis tool for T1D in new onset diabetic patients, circulating autoantibodies against β cell proteins (specificity and quantity) in at-risk individuals, as well as abnormalities in the oral glucose tolerance test, can generally help predict the risk of, and time remaining, before the onset of hyperglycemia [9]. These predictive data have raised the possibility of attempting therapeutic intervention before the onset of hyperglycemia in high-risk individuals identified based on biomarkers like those mentioned above. Prevention of T1D may represent a viable alternative to an actual cure by permanently blocking the autoimmune response while there are sufficient β cells remaining, and may offer a more cost-effective approach in the short-term to deal with the alarming rise in the incidence of disease (Fig. 1). To make the matter even more complex, many patients may present a spontaneous but temporary remission after onset, known as the honeymoon period, possibly reflecting reduced stress on residual β cells after initial insulin treatment. This honeymoon period may perhaps represent a sweet window of opportunity (pun intended) to exploit for the use of intervention therapy.

In this review, we will discuss how our therapeutic arsenal to fend off this autoimmune disease has greatly diversified beyond traditional drugs and biologicals to include various forms of cell therapies, as well as other less conventional approaches. The field is witnessing a paradigm shift from immunosuppressive therapies applied after the onset of hyperglycemia (a time at which β cell function has generally been irreversibly lost) to prevention strategies attempting to shut off the autoimmune response and preserve β cell function in high-risk individuals. This of course entails the use of reliable biomarkers to identify the most appropriate at-risk subjects for such intervention trials, and perhaps also guide the type of therapy that should be employed, paving the way to more personalized therapies. Current studies using new techniques of transcriptomics and proteomics [10–13] are attempting to more precisely stratify those at risk by identifying novel biomarkers that may be superior to those currently used to define the stage or rate of progression of disease, and thus help select appropriate subjects to enter into prevention trials. Although the strategies described in this review have all shown remarkable efficacy in preclinical models, it should be noted that little or no clinical efficacy data is available for most of them, whether they are evaluated in the treatment of recent onset patients after safety has been demonstrated or in prevention studies following safe but ineffective use in recent onset patients.

**Figure 1.** T1D incidence has doubled every 20 years. Data for Finland are from the Finnish National Public Health Institute; data for Sweden are from the Swedish Childhood Diabetes Registry; data for Colorado are from the Colorado IDDM Registry, the Barbara Davis Center for Childhood Diabetes, and SEARCH for Diabetess in Youth; data for Germany are a compilation of two reports; and data from Poland are from Diabetologia 2010;54:508-515. Reprinted with permission from the Ann NY Acad Sci 2008;1150:1-13, with additional modifications and permission from Marian Rewers and Jay Skyler.

**A Shift from Treatment to Prevention Is Driven by Biomarkers Guiding When and How to Intervene**

The progress in identifying the patients who are at “high-risk” and should be entered into prevention trials has been supported by an improved understanding of T1D disease processes that allows screening for at-risk individuals and stratification of the individual’s risk and time of progression to the development of hyperglycemia. The first level of screening is comprised of family history (number of relatives with T1D and degree of relationship) and HLA haplotype (HLA-DR3/4 heterozygosity combined with HLA-DQ8 conferring the highest known risk) [9]. Although these risk factors are fixed from birth, new relatives may become diagnosed later and the relative risk re-evaluated. These parameters have served to enroll young subjects into studies on how environmental factors influence disease progression (e.g., primary prevention studies examining diet alterations in genetically at-risk babies with no evidence of autoimmunity, Table 1). These individuals can be closely and regularly monitored and undergo a second level of screening consisting of well-established biomarkers such as circulating autoantibodies to β cell antigens insulin, GAD65, IA-2, ZnT8, and IGRP [9, 14], which have served as good predictive tools [15–18] and enrollment criteria for prevention studies. In vitro immunosays performed on peripheral blood cells including T cell responses to β cell antigens or identification of diabetogenic T cells by tetramer staining complete this assessment of the breadth (how many autoantigens targeted) and amplitude (antibody titers or frequency of tetramer-positive T cells) of the autoimmune response [14]. More recently, biomarkers based on epigenetic changes have been discovered, such as circulating demethylated insulin DNA [19, 20] and differences in methylation level at specific CpG sites in immune cells [21]. Increased levels of demethylated insulin DNA in the blood correlates with the extent of β cell damage [19], while the extent of insulinis may now be evaluated by refined imaging techniques [22].

These biomarkers of prediction are important to evaluate disease risk and rate of progression (indicating with a high degree of confidence if and approximately when a patient will progress to overt hyperglycemia unless the course of progression is altered by treatment), and, therefore, to determine when to treat. Individuals with a comparable risk level may experience a different rate of progression, according to their genetic makeup (other genes besides HLA) and their environment, which differentially affect mechanisms of immune tolerance and pathogenesis. As environmental factors change, the rate of progression may increase or decrease, placing the subject at greater risk or slowing down the development of the


Table 1. Main clinical trials focused on the prevention of T1D

| Prevention trials                                      | Drug                                    | Type of study          |
|--------------------------------------------------------|-----------------------------------------|------------------------|
| Diet/supplement-based prevention                        |                                         |                        |
| NCT01055080 (FINDia)                                   | Baby diet alteration                    | Phase 1, primary prevention |
| NCT00570102 (MIP)                                      | Baby diet alteration                    | Phase 2, primary prevention |
| NCT01115621 (BABYDIET)                                 | Baby diet, delayed gluten               | Phase 1, primary prevention |
| NCT00179777 (TRIGR)                                    | Controlled diet in infants              | Phase 2, primary prevention |
| NCT003333554 (NIDDK)                                   | Omega-3-fatty acids                     | Phase 2, primary prevention |
| NCT00141986 (CDA)                                      | Vitamin D                               | Phase 1, primary prevention |
| β cell antigen-based prevention                        |                                         |                        |
| NCT00004948 (DPT-1)                                    | Parenteral or oral insulin              | Phase 2, secondary prevention |
| NCT00419562 (NIDDK)                                    | Oral insulin                            | Phase 3, secondary prevention |
| ISRCTN76104595 (Pre-POINT)                            | Oral insulin                            | Phase 1, primary prevention |
| NCT00654121 (BDR Trial)                                | Subcut. insulin (Actrapid HM)           | Phase 2, secondary prevention |
| NCT00223613 (DIPPP)                                    | Intranasal insulin                      | Phase 3, secondary prevention |
| NCT00336674 (INIT-II)                                  | Intranasal insulin                      | Phase 2, secondary prevention |
| NCT01122446 (DIAPREV-IT)                               | Diamyd (GAD-Alum)                       | Phase 2, secondary prevention |
| Combinations of the above                               |                                         |                        |
| NCT02387164 (DIAPREV-IT2)                              | Diamyd (GAD-Alum + Vit. D)              | Phase 2, secondary prevention |
| Prevention using biological-based immunotherapy         |                                         |                        |
| NCT01773707 (NIDDK, TN18)                              | Abatacept (CTLA4-ig)                    | Phase 2, secondary prevention |
| NCT01030861 (NIDDK, TN10)                              | Teplizumab (anti-CD3)                   | Phase 2, secondary prevention |
| Cell-based prevention                                   |                                         |                        |
| CoRD study (Sydney)                                    | Umbilical cord blood                    | Phase 1, secondary prevention |

Note: Clinical trials are color-shaded based on whether they are completed, ongoing, or planned.

Disease (Fig. 2). As a result of multiple etiological factors acting in concert, the disease can progress from very fast in the case of fulminant T1D [23] to very slow in the case of latent autoimmune diabetes in adults (LADA) [24]. However, the most aggressive forms of disease, like fulminant T1D, might not benefit from prevention unless the trigger becomes well understood.

Because of the heterogeneity of etiological factors that may control the rate of progression, it is unlikely that patients stratified as having a similar risk will be equally responsive to a particular treatment (Table 2). Treating a high-risk patient with the wrong drug would cost precious time during which β cells will continue to be destroyed. In prevention studies, as opposed to new onset cases, more time will be needed before it can be determined whether the treatment is effective. Conversely, treating a low-risk patient, who may never advance to onset, even with the right prevention therapy, would involve unnecessary costs and risks. Thus, a third level of screening that is more sophisticated (using novel biomarkers featured in larger datasets) will be required to help determine how best to treat each patient by providing clues as to the underlying defects that need to be acted upon. A combination of genetic, transcriptomic, and proteomic tests performed on blood samples will likely be part of such screening in the future, and extensive research is being conducted to this end. Furthermore, advances in viromics have enabled the development of sensitive blood tests that can detect prior exposure to particular viruses, some of which have long been suspected to play a role as a trigger for the disease in some individuals [44]. If these tests help confirm a link between these pathogens (which are not uncommon, and therefore would not be sufficient to induce T1D), then the prospect of vaccinating genetically at-risk individuals becomes possible.

In recent years, it has become clear that combination therapies, selected to address multiple underlying defects, will become more prominent in our effort to tackle T1D heterogeneity in both prevention and treatment. Such combination therapies are expected to be effective in larger cohorts of patients with overlapping defects. Although many of the immunosuppressive strategies have not been effective when administered post-hyperglycemia, they might be appropriate to use at an earlier stage of disease where they may prove more efficacious. Besides efficacy and safety, the cost will
need to be leveraged against the long-term benefits. Expensive therapies that induce durable tolerance and protection may, however, save money in the long run. It is unusual for new drugs to be approved for prevention of disease without prior testing in new-onset patients: the immunomodulatory drugs and cell-based therapies described below are no exception to this rule.

### OVERVIEW OF THE CURRENT LANDSCAPE OF NON-CELL THERAPIES

#### Cell- or Pathway-Neutralizing Biologics

Regulatory authorities have historically prioritized treatment of new onset patients because these cases are more pressing, the risk tolerance greater, and the studies shorter, smaller, and less expensive. In an attempt to replace the use of globally immunosuppressive drugs, a number of promising biologics have been evaluated in new onset patients, such as anti-CD3 mAb [49–51], anti-CD20 mAb [52], CTLA4-Ig [53]. These drugs showed significant but limited (transient) efficacy in new-onset patients. These drugs are now being tested in high-risk normoglycemic patients where they might have a more pronounced and durable effect in sustaining euglycemia (Table 1). These drugs were deemed safe enough by the US Food and Drug Administration to be used prophylactically at a dose unlikely to cause serious adverse events.

Current studies using such biologics to prevent disease in high-risk patients include two major TrialNet studies: TN10 (Clinical-Trial.gov NCT01030861) using Tepilizumab (anti-CD3 mAb) and TN18 (ClinicalTriall.gov NCT01773707) using Abatacept (CTLA4-Ig). Many other biologics used to treat other autoimmune diseases are also being evaluated for T1D. However, these drugs remain relatively nonspecific and may still carry accrued risks of infections or malignancies in susceptible subjects.

#### Low Dose IL-2: A Safer and More Selective Approach?

Because of different sensitivities, it was found that regulatory T cells (Tregs), a subset of T cells that protects from autoimmune disease (GvHD) [55–57] and hepatitis C virus-induced vasculitis [58, 59], and preliminary studies on its use as a potential treatment of T1D [60]. In addition, preclinical studies in non-obese diabetic (NOD) mice showed that low dose IL-2 administered after onset of hyperglycemia restored euglycemia in a majority of the treated mice [61]. In each instance, low dose IL-2 therapy was associated with a dose-dependent increase in the number of circulating Tregs and a marked diminution of inflammatory cytokine expression in the serum of the
treated mice or patients in the initial short-term safety trial [60]. An additional dose finding study to determine the optimal dose of IL-2 required to increase the number and response of Tregs has been completed in T1D patients (ClinicalTrial.gov NCT01827735). Subsequently, an efficacy trial has begun in patients with recent onset T1D (ClinicalTrial.gov NCT01862120). Once these studies (in Table 3) are completed and the safety profile confirmed, a move to recruit high-risk patients in low dose IL-2 studies will be expected.

However, the potential success of low dose IL-2 therapy in T1D patients rests on two assumptions: (i) Tregs are functionally defective and (ii) IL-2 production is impaired. Studies on whether CD4<sup>+</sup> CD25<sup>+</sup> Tregs are defective in T1D have yielded conflicting results (decreased frequency [62], decreased function [63], or normal frequency and function [64]), which may reflect inadequate identification of Tregs by available markers; recruitment of patients different in age and disease progression and differences in experimental conditions. Follow-up studies using more specific markers (FOXP3<sup>+</sup> CD127<sup>low</sup> and demethylation of regulatory elements of the FOXP3 gene) showed that both the frequency and function of Tregs are normal in the blood of T1D patients, even though a transient decrease of suppressor activity may occur early after diagnosis [65], and in a subset of T1D patients [30]. Studies from the Battaglia lab showed that reduced suppressive function of Tregs may be restricted to the pancreatic lymph nodes in patients with long lasting T1D [31]. A defect in IL-2 production by total peripheral blood mononuclear cells of patients with new onset T1D was reported several years ago [66] but never confirmed as a key immunological feature of T1D patients. A recent study showed that the T1D-susceptibility IL2RA haplotype identified by rs12722495 is associated with decreased signaling via the IL-2 pathway in both memory T cells and Tregs and that this is linked to diminished Treg function [32]. However, this phenotype is limited to carriers of this single nucleotide polymorphism (SNP) and not to all individuals. Thus, it is likely that this treatment may benefit some patients more than others, again based on their underlying defects that contribute to disease.

### Table 3. Main clinical trials using low-dose IL-2 or cell-based therapies in recent onset T1D patients

| New onset trials | Drug | Type of study |
|------------------|------|--------------|
| **Low-dose IL-2** |      |              |
| NCT01827735 (DILT1D) | Proleukin (IL-2) | Phase 1/2, onset < 24 months |
| NCT02265809 (DILfrequency) | Aldesleukin (IL-2) | Phase 1/2, onset < 60 months |
| NCT01353833 (DF-IL2) | Aldesleukin (IL-2) | Phase 1/2, onset < 24 months |
| NCT01862120 (DFIL2-Child) | IL-2 | Phase 2, recent onset |
| NCT02411253 (DIABIL-2) | rhIL-2 | Phase 2, recent onset |

| Cell-based therapies |      |              |
|----------------------|------|--------------|
| ISRCTN06128462 (Gdansk) | Polyclonal Tregs | Phase 1, onset < 2 months |
| NCT01210664 (UCSF) | Polyclonal Tregs | Phase 1, onset 3-24 months |
| NCT00445913 (Pittsburgh) | Autologous DCs | Phase 1, long-term T1D (5y+) |
| NCT02354911 (Pittsburgh) | Autologous DCs | Phase 2, new onset < 100d |
| NCT01068951 (Uppsala) | MSCs | Phase 1, new onset |
| NCT00690066 (Mesoblast) | Prochymal (MSCs) | Phase 2, onset 2-20 wks |
| NCT02057211 (Uppsala) | MSCs | Phase 2, new onset < 3 weeks |
| NCT01322789 (Sao Paulo) | MSCs | Phase 1/2, new onset < 6 weeks |
| NCT00305344 (Florida) | Umbilical cord blood (UCB) | Phase 1/2, post-onset |
| NCT00989547 (Munich) | Umbilical cord blood (UCB) | Phase 1, post-onset |
| NCT01350219 (Tianhe) | UCB-derived stem cells | Phase 2, post-onset |
| NCT01996228 (Tianhe) | UCB-derived stem cells | Phase 1/2, post-onset |
| NCT00315133 (Sao Paulo) | Autologous HSCs | Phase 1/2, onset < 12 weeks |
| NCT01285934 (Northernwest) | Autologous HSCs | Phase 1/2, onset < 5 months |

Note: Clinical trials are color-shaded based on whether they are completed, ongoing, or planned. Stem cells used for the generation of new β cells are not covered here. DCs: dendritic cells; HSCs: hematopoietic stem cells; MSCs: mesenchymal stem/stromal cells; Tregs: regulatory T cells.

A Wide Array of Approaches to Reestablish Antigen-Specific Tolerance

The overall objective of this strategy is to deliver β cell antigens in particular ways such that their presentation in vivo results in elimination or inactivation of antigen-specific diabetogenic T cells, or induction of antigen-specific immunoregulatory populations, to confer durable protection from autoimmunity without compromising the general immunosurveillance for infectious agents and malignant cells. The traditional method has been to administer protein antigens via tolerogenic routes (mainly oral or intranasal insulin and GAD65/Alum), but this approach has not produced significant clinical benefit in recent onset patients [67]. Because of lack of adverse side effects, these therapies are now being tested in secondary prevention trials (i.e., in patients with ongoing autoimmune phenomena by circulating autoantibodies) (Table 1). It is worth pointing out that oral insulin has also been tested in a primary prevention trial (in young subject with no evidence of autoimmunity, Pre-POINT trial, Table 1) and data suggest that insulin-specific Tregs were induced at the highest dose [68]. Antigens coupled with apoptotic cells have been known for several decades to be very tolerogenic and showed efficacy in preclinical models of T1D [69]. This strategy has now been tested in patients with multiple sclerosis and was well tolerated [70]. Massive apoptosis resulting from depletion of B cells and CD8<sup>+</sup> T cells (using a short course of biologics) is accompanied by release of TGF-β, which combined with exogenous antigens such as GAD65 peptides, supports the generation of protective Tregs, because CD4<sup>+</sup> T cells are left untouched and available for conversion [71]. This promising approach validated in mouse models of T1D and multiple sclerosis remains to be tested for safety in humans.

A less conventional alternative to protein antigen delivery lets the body produce specific antigens in cells or sites...
Cell-based therapies are individualized approaches that currently involve the transfer of autologous cells that have immunoregulatory properties and can provide a counterbalance for effector T cells that mediate β cell destruction. While certain drugs aim at expanding and potentiating Tregs in vivo (see low dose IL-2 above), cell-based therapies generally involve Tregs or cells that have the ability to induce or potentiate such immunoregulatory populations in vivo. We will also discuss the use of different types of stem cells as part of cell-based therapies to block autoimmune responses, but we will not cover the generation of new β cells from stem cells for transplantation, which is reviewed elsewhere [82].

Regulatory T Cells (Tregs)

Several preclinical animal studies have established that the adoptive transfer of Tregs can prevent various autoimmune diseases, T1D included. However, only a few studies showed that Treg cell transfer is efficacious in reverting active disease and, when it occurred, the transferred cells needed to be antigen-specific [83–85]. Based on this evidence, Tregs are now being used in phase 1/2 studies in patients with autoimmune diseases [86]. Increasing doses of autologous ex vivo–expanded polyclonal CD4⁺CD25⁺ Tregs have been used safely in newly diagnosed T1D patients [87]. These studies were instrumental in demonstrating the safety and feasibility of such a complex approach of personalized medicine, but efficacy has still to be demonstrated in larger trials.

Based on the data in animal models, to be of any therapeutic use, Tregs have to be transferred prior to overt hyperglycemia or have to be antigen-specific. It has been, up to now, difficult to obtain sufficient antigen-specific CD4⁺FoxP3⁺ Tregs, but this might be more feasible by inducing Tregs de novo in vitro. Such an approach has been used in the context of allogeneic hematopoietic stem cell transplantation to prevent GvHD where host-specific Tr1 cells were generated in vitro from donor peripheral blood and transferred to transplanted hosts [88]. The induction of self-specific Tr1 cells in NOD mice in vivo is feasible and they protect from diabetes development [89]. However, the generation of human diabetes-related antigen-specific Tregs in vitro has yet to be achieved. Studies on adoptive T cell therapy have demonstrated the possibility of engineering T cells using lentivirus, either by expressing a relevant (β cell antigen-specific) T cell receptor into polyclonal Tregs [90] or by overexpressing FoxP3 in T cells [91], potentially in antigen-specific T cells that have been enriched and ex vivo expanded.

Regulatory B Cells (Bregs)

Recently, the IL-10–producing regulatory Bregs have attracted attention as being altered in autoimmune diseases and thus represent another potential tool for cell therapy [92]. As with Tregs, their numbers and function might be compromised in T1D patients [93], indicating the possibility of using Breg therapy, alone or in concert with Tregs. However, the importance of antigen-specificity in this case is not clear, and considering that we are still at the beginning of cell therapy with Tregs, using Bregs is even more futuristic.

Dendritic Cells

As the most specialized of APCs, dendritic cells (DCs) have long been a candidate of choice for their ability to engage T cells through presentation of β cell antigens, and under a tolerogenic phenotype, to achieve deletion or inactivation of diabetogenic T cells, converting them into Tregs or restimulating preexisting Tregs. DC infusions have shown remarkable efficacy in numerous preclinical studies, even in the absence of exogenously provided antigens [94]. The first clinical trial using autologous DCs in recent onset T1D patients demonstrated both safety and the potential to induce Bregs [95]. In this phase 1 study, the first of its kind for the treatment of autoimmune diseases, the monoocyte-derived DCs were locked in a nonimmunogenic state by silencing important costimulatory molecules (CD40, CD80, and CD86), but were not provided exogenous antigen. Autoantigen expression and maturation stage are two crucial considerations, because immunogenic DCs expressing β cell antigens could boost autoimmune T cell
responses against β cells. The antigen-specific therapies previously described rely on the acquisition and presentation of relevant antigens by tolerogenic APCs that are not that well characterized but possibly comprising different subsets of DCs and other types of APCs. In the case of the recent DC trial, the mechanism of action is not completely understood as no exogenous antigen was provided, and whether these DCs could pick up and present relevant autoantigens in vivo remains unclear. Furthermore, there is evidence that DCs expressing costimulatory molecules but not inflammatory cytokines (termed semimature DCs) may induce tolerance as well [96].

Another phase 1 trial employing tolerogenic DCs pulsed with citrullinated peptides for the treatment of rheumatoid arthritis has demonstrated safety as well as immunological responses reflective of regulation [97], suggesting that provision of autoantigens may not lead to exacerbated responses as long as the DCs are maintained tolerogenic, which in this case was achieved by pretreatment with an NF-κB inhibitor. An alternative or complementary approach to silencing the expression of costimulatory genes is the overexpression of tolleric, and can provide protection even in an allogeneic host, which makes them attractive for the clinic [108]. They have been proven to be well-tolerated in T1D patients whether they were isolated by bone marrow aspiration [109] or from adipose tissue [110], and associated with improvement of disease parameters such as C-peptide preservation. Careful characterization of the phenotype and properties of MSCs used in cell therapy is crucial to demonstrate consistency between studies and draw meaningful conclusions, regardless of the source of the cells, isolation, and culture conditions (Table 4). Two follow-up clinical trials are currently recruiting in Sweden and Brazil to demonstrate long-term efficacy (Table 3). All trials so far are being conducted in recently diagnosed T1D patients using MSCs that are either autologous or from first-degree relatives. Although no serious side effects have been reported so far, there remains a concern that slow growing tumors may appear in the long term in some patients receiving autologous cells, according to some preclinical studies [108].

**Umbilical Cord Blood**

Although this approach is limited to a few individuals who have banked samples, umbilical cord blood (UCB) is a great source of abundant MSCs and Tregs, which might work in synergy when infused into patients. As many important self-reactive Tregs appear to be released early in life [111], these Tregs may also include more antigen-specific Tregs of relevance. Autologous UCB infusion was found to be safe but did not have any significant therapeutic effect despite increased numbers of Tregs [112, 113] and even with oral docosahexaenoic acid and vitamin D supplementation [114]. Another phase 1 trial, also in new onset pediatric subjects, is well under way in Germany (Table 3). As previously mentioned, it is possible that therapies involving Tregs would be more effective when applied prior to disease onset. In that model, the Cord Reinfusion in Diabetes (CoRD) study, enrolling high-risk children with banked UCB, was recently initiated in Australia and represents the first cell-based therapy used for secondary prevention of diabetes [115]. A distinct process is being tested in China, whereby lymphocytes are obtained from the blood by leukapheresis, “reeducated” *ex vivo* in contact with UCB-derived stem cells, and then reinfused into the patient. These studies suggest that this treatment improved preservation of β cell function without notable adverse effects, but caution must be exercised in the interpretation of these studies, which were improperly controlled [116].

**Mesenchymal Stem/Stromal Cells**

Mesenchymal stem/stromal cells (MSCs) are endowed with regenerative and immunosuppressive properties that have fueled their popularity in cell therapy, yet controversies remain regarding their name and definition [103]. Although they can generally suppress immune responses on their own in a nonspecific manner, they have also been shown to induce or expand Tregs, including in preclinical T1D studies [104–106]. Because MSCs are nonprofessional APCs, it is unclear if and how they specifically interact with Tregs and diabetogenic T cells, and their effect may be indirect through inflammation relief [107]. Unlike DCs, MSCs are nonimmunogenic, and can provide protection even in an allogeneic host,
circulating T cells and their replacement with hematopoietic stem cells (HSCs). Multiple completed studies have involved autologous HSCs mobilized from peripheral blood and administered after a nonmyeloablative regimen consisting of cyclophosphamide and anti-thymocyte globulin [117–119]. This treatment performed in new-onset T1D patients demonstrated a remarkable ability to normalize glycemia in a majority of the subjects. Independence from insulin lasted between several months and several years, up to 3-4 years (as reported in the last meeting of the Immunology of Diabetes Society), and a larger trial is now enrolling patients (ClinicalTrial.gov NCT01285934). However, this therapy is fraught with considerable side effects associated with the nonmyeloablative regimen [117–119], which make this approach unattractive in its current form to many prospective patients and precludes its use for prevention. Furthermore, the contribution of HSCs in maintaining normoglycemia is unclear as the immunosuppressive effect of the regimen may account for part if not all of the therapeutic benefit. Finally, new T cells (and other immune cells) generated from autologous HSCs would still carry any inherent genetic defects that may play a role in disease etiology. Transplantation of bone marrow–derived allogeneic HSCs with induction of mixed chimerism has also been tested in a minority of patients with autoimmunity, including T1D [120]. The use of HSCs in combination with islet transplant to induce chimerism and immunological tolerance has been tested in a recent trial at the University of Miami based on campath-1H and infusion of donor CD34+ HSCs (ClinicalTrials.gov NCT00315614), but did not show any significant benefit. Although allogeneic HSCs from a compatible and healthy donor may help correct some genetic abnormalities, this must be preceded by high doses of chemotherapy and radiation to ablate the patient’s bone marrow and is followed by prolonged immunosuppression to prevent GvHD. The consequent transplant-related morbidity and mortality limit this approach to patients with hematological malignancies [121]. It should be noted that preclinical data with purified allogeneic CD34+CD90+ HSCs showed complete reversion of T1D in the absence of GvHD [122]. In addition, novel biologicals are under investigation for use as safer and less toxic drugs to myeloablate the patient’s bone marrow [123]. Thus, as safer and more effective HSC transplantation protocols become available, allogeneic HSCs might also be indicated in T1D. A more detailed review of the different applications of stem cells (including MSCs and UCB) to T1D can be found elsewhere [124].

In parallel to efforts in generating insulin-producing cells from stem cells (embryonic stem cells or induced pluripotent stem cells) [82], there is an expanded interest in growing tissues specialized in tolerance induction, such as thymic tissue [125, 126]. Although much can be learned from these studies, the clinical implementation of such advances is elusive, including where and how to implement the new tissue.

**Conclusion**

A variety of original therapeutic strategies for treating or preventing T1D have emerged in the past decade, with the latest approaches clearly dominated by cell-based therapies. As the least expensive and most conventional therapies have failed to deliver efficient and durable protection from diabetogenic immune responses, testing of more expensive, and individualized therapies has become justified as long as preclinical studies indicate a strong prospect of durable efficacy achieved with a minimal number of treatments. Strategies that are more antigen-specific and less immunosuppressive tend to have the best safety profile, and their poor efficacy in new onset patients should not discourage evaluation in prevention trials in high-risk patients in which they might perform surprisingly well. The enrollment of subjects for prevention studies should be guided by more refined biomarkers, which may help the diabetes community to better understand the underlying defects behind the autoimmune response in each patient, and better tailor the treatment type, dose, and timing. When appropriate, two or more of these therapies may be combined in order to address multiple defects and benefit a larger number of patients. A clear advantage of cell-based therapies is that they can perform multiple tasks. For example, one can envision tolerogenic APCs engineered to express selected β cell antigens (to specifically engage diabetogenic T cells), additional immunoregulatory ligands or cytokines (to potentiate T cell deletion or Treg induction), homing molecules (for targeting to inflamed islets or their draining lymph nodes), anti-inflammatory cytokines (to quench inflammation), and even growth factors to promote β cell replication.

**Acknowledgments**

RJC is currently funded by the National Institutes of Health (NIH), the Diabetes & Endocrinology Research Center (Columbia University), and the Irving Institute for Clinical and Translational Research; MB by the Italian Ministry of Health, the European Community, the Cariplo Foundation, and the Juvenile Diabetes Research Foundation (JDRF); MGR by the Italian Telethon Foundation and JDRF; and CGF by the NIH and JDRF.

**Author Contributions**

All authors wrote and edited the manuscript.
Randomized Control Trial Group. Diabetes 1988;37:1574–1582.

7. Fields GS, Sikanta S, Jackson R et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985;2:271–276.

8. Todd JA. Etiology of type 1 diabetes. Immunity 2010;32:457–478.

9. Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity 2010;32:468–478.

10. Kaizer EC, Glaser CL, Chausabel D et al. Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab 2007;92:3705–3711.

11. Jin Y, She JX. Novel biomarkers in type 1 diabetes. Rev Diabet Stud 2012;9:224–235.

12. Jin Y, Sharma A, Bai S et al. Risk of type 1 diabetes in islet autoantibody-positive children can be further stratified using expression patterns of multiple genes implicated in peripheral blood lymphocyte activation and function. Diabetes 2014;63:2506–2515.

13. Kallionpaa H, Elo LL, Laajala E et al. Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility. Diabetes 2014;63:2402–2414.

14. Toole JC, Herold KC. Biomarkers in type 1 diabetes: Application to the clinical trial setting. Curr Opin Endocrinol Diabetes Obes 2014;21:287–292.

15. Kulmala P, Savola K, Petersen JS et al. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest 1998;101:327–336.

16. LaGasse JM, Braulte MS, Leech NJ et al. Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: An 8-year follow-up of the Washington State Diabetes Prediction Study, Diabetes Care 2002;25:505–511.

17. Bingley PJ, Gale EA. European Nicotinamide Diabetes Intervention Trial G. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: The role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006;49:881–890.

18. Sosenko JM, Krischer JP, Palmer JP et al. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care 2008;31:528–533.

19. Akirav EM, Lebastchi J, Galvan EM et al. Detection of beta-cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci USA 2011;108:19018–19023.

20. Herold KC, Usmani-Brown S, Ghazi T et al. Beta cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest 2015;125:1163–1173.

21. Rawayk VN, Byean H, Down TA et al. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet 2011;7:e1002300.
Unconventional Approaches to Treat Type 1 Diabetes

54 Yu A, Snowhite I, Vendrame F et al. Selective II-6 responsiveness of regulatory T cells: A proof-of-principle intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 2015;64:2172–2183.

55 Koretz J, Matsuoka K, Kim HT et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2013;365:2055–2066.

56 Matsuoka K, Koreth J, Kim HT et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013;5:197ra143.

57 Kennedy-Nasser AA, Ku S, Castillo-Car P et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antiviral stimulating activity. J Clin Cancer Res 2014;20:2215–2225.

58 Saadoun D, Rensonwaig M, Joly F et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2012;367:2057–2077.

59 Oo YH, Mutimer D, Adams DH. Low-dose interleukin-2 and HCV-induced vasculitides. N Engl J Med 2012;366:1353–1354; author reply 1354.

60 Hartemann A, Bensimon G, Payan CA et al. Low-dose interleukin 2 in patients with type 1 diabetes: A phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013;1:295–305.

61 Grinberg-Bleyer Y, Baeyens A, You S et al. Acquired defect in interleukin-2 gene therapy. Transl Res 2013;161:230–240.

62 Kaye WA, Adri MN, Soeldner JS et al. Improved efficacy of a tolerizing DNA vaccine for reversal of experimental type 1 diabetes through enhancement of gene expression and localization to intracellular sites. J Immunol 2008;181:8298–8307.

63 Luth S, Huber S, Schramm C et al. Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune diabetes in NOD mice by inducing peripheral immune tolerance. J Immunol 2008;201:394–398.

64 Putnam AL, Vendrame F, Dotta F et al. CD4(+)CD25(+) regulatory T cells from patients with type 1 diabetes. Diabetes 2005;54:92–99.

65 Hughson A, Bromberg I, Johnson B et al. Enhanced immunologic outcome in haploidentical-HSC transplanted patients treated with IL-10-merized donor T cells. Front Immunol 2014;5:167.

66 Batillia M, Stabilini A, Draghi E et al. Induction of tolerance in type 1 diabetes via both CD4(+CD25(+T regulatory cells and T type 1 regulatory cells. Diabetes 2006;55:1571–1580.

67 Brusco TM, Koya R, Zhu S et al. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One 2010;5:e11726.

68 Allan SE, Alkadad AN, Merindol N et al. Generation of potent and stable human CD4(+)CD25(+) regulatory cells by activation-independent expression of FOXP3. Mol Ther 2008;16:194–202.

69 Regeil S, Vergani A, Tezza S et al. Interleukin-10 and regulatory T cells arise within antigen-experienced COAD + B cells to maintain tolerance to islet autoantigens. Diabetes 2015;64:158–171.

70 Creusot RJ, Giannoukakis N, Trucco M et al. It’s time to bring dendritic cell therapy to type 1 diabetes. Diabetes 2014;63:20–30.

71 Giannoukakis N, Phillips B, Finegold D et al. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011;34:2026–2032.

72 Gordon JR, Ma Y, Churchman L et al. Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol 2014;5:7.

73 Benham H, Neel HJ, Law SC et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med 2015;7:290ra287.

74 Schinnerling K, Soto L, Garcia-Gonzalez P et al. Skewing dendritic cell differentiation towards a tolerogenic state for recovery of tolerance in rheumatoid arthritis. Autoimmun Rev 2015;14:517–527.

75 Kyte JA, Gaudernack G. Immune-gene therapy of cancer with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother 2006;55:1432–1442.

76 Shurin MR, Gregory M, Morris JC et al. Genetically modified dendritic cells in cancer immunotherapy: A better tomorrow? Expert Opin Biol Ther 2010;10:1539–1553.

77 Bonehill A, Tuyaerts S, Van Nuffel A et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 2009;17:1170–1181.

78 Creusot RJ, Chang P, Healey DG et al. A short pulse of IL-4 delivered by DCs electro porous with modified mRNA can both pre-
vent and treat autoimmune diabetes in NOD mice. Mol Ther 2010;18:2112–2120.

103 Bianco P. “Mesenchymal” stem cells. Annu Rev Cell Dev Biol 2014;30:677–704.

104 Madec AM, Malloine R, Afonso G et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009;52:1391–1399.

105 Bassi EI, Moraes-Vieira PM, Moreira-Sa CS et al. Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes 2012;61:2534–2545.

106 Kota DJ, Wiggins LL, Yoon N et al. TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity. Diabetes 2013;62:2048–2058.

107 Burr SP, Dazzi F, Garden OA. Mesenchymal stromal cells and regulatory T cells: The Yin and Yang of peripheral tolerance? Immuno Cell Biol 2013;91:12–18.

108 Fiorina P, Jurewicz M, Augello A et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009;183:993–1004.

109 Carlsson PO, Schwarz E, Korsgren O et al. Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 2015;64:587–592.

110 Thakkar UG, Trivedi HL, Vanikar AV et al. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy 2015;17:940–947.

111 Yang S, Fujikado N, Kolodin D et al. Immune tolerance. Regulatory T cells generated early in life play a distinct role in maintaining self-tolerance. Science 2015;348:589–594.

112 Haller MJ, Wasserfall CH, Hulme MA et al. Autologous umbilical cord blood transplantation in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care 2011;34:2567–2569.

113 Giannopoulou EZ, Puff R, Beyerlein A et al. Effect of a single autologous cord blood infusion on beta-cell and immune function in children with new onset type 1 diabetes: A non-randomized, controlled trial. Pediatr Diabetes 2014;15:100–109.

114 Haller MJ, Wasserfall CH, Hulme MA et al. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. Biol Blood Marrow Transplant 2013;19:1126–1129.

115 Han MX, Craig ME. Research using autologous cord blood - Time for a policy change. Med J Aust 2013;199:288–299.

116 Zhao X, Jiang Z, Zhao T et al. Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med 2012;10:3.

117 Voltarelli JC, Couri CE, Stracieri AB et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009;301:1573–1579.

118 Parent AV, Russ HA, Khan IS et al. Generation of functional thymic epithelium from human embryonic stem cells that supports host T cell development. Cell Stem Cell 2013;13:219–229.